Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.54 |
| ▸ | BCL2 | P10415 | 1/20 | 0.54 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | LAP3 | P28838 | 1/20 | 0.50 |
| ▸ | YAP1 | P46937 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420857 | 0.89 | ATM (0.55) | LTA4H | |
| SCHEMBL7806363 | 0.85 | LTA4H (0.56) | LTA4HBCL2LNPEPPTPN1LAP3 | |
| SCHEMBL7338836 | 0.84 | LTA4H (0.65) | LTA4HLNPEPLAP3PPARG | |
| SCHEMBL7339057 | 0.84 | LTA4H (0.65) | LTA4HLNPEPLAP3PPARG | |
| SCHEMBL7338844 | 0.84 | LTA4H (0.65) | LTA4HLNPEPLAP3PPARG | |
| SCHEMBL2860639 | 0.83 | LTA4H (0.61) | LTA4HLNPEPLAP3PPARG | |
| SCHEMBL5832735 | 0.83 | LTA4H (0.61) | LTA4HLNPEPLAP3PPARG | |
| Hydrochloric Acid SCHEMBL5832752 | 0.82 | LTA4H (0.60) | LTA4HLNPEPLAP3PPARG | |
| Hydrochloric Acid SCHEMBL5832756 | 0.82 | LTA4H (0.60) | LTA4HLNPEPLAP3PPARG | |
| SCHEMBL7281929 | 0.82 | MMP9 (0.63) | LTA4HLNPEPLAP3PPARGMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | LTA4H 1788/4885BCL2 2066/4885LNPEP 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.